XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.63 and traded as high as $2.88. XTL Biopharmaceuticals shares last traded at $2.86, with a volume of 4,334 shares.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, XTL Biopharmaceuticals presently has an average rating of “Sell”.
View Our Latest Analysis on XTL Biopharmaceuticals
XTL Biopharmaceuticals Stock Performance
XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) last released its earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The firm had revenue of ($0.26) million during the quarter.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Further Reading
- Five stocks we like better than XTL Biopharmaceuticals
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
